Non-invasive Assessment of Insulin Resistance

描述(由申请人提供)：该项目的长期目标是开发一种新的非侵入性胰岛素抵抗测试。建议的测试是基于细胞呼吸过程中葡萄糖氧化(GOX)和脂肪氧化(LOX)之间的反向关系这一公认的原则。由于口服13C-葡萄糖作为口服葡萄糖耐量试验(OGTT)的一部分，根据呼气二氧化碳的同位素分析，可以精确地测量全身Gox/Lox的比率，因此我们建议可以开发一种合适的非侵入性胰岛素抵抗试验。在第一阶段，我们建议对不同胰岛素抵抗范围的个体进行有限的临床方案，以证明拟议的测试与目前最有用的胰岛素抵抗临床测试之间的预期反向关系；即全身胰岛素敏感指数(WBISI)。在H阶段，我们将进行一些专门设计的临床方案，以检查潜在的重要参数(实验和生理)对此测试性能参数的影响。我们预计，I期和H期拟议研究的成功完成将导致一种专利产品--专门用于胰岛素抵抗的非侵入性评估的方法。

DESCRIPTION (provided by applicant): The long-term objectives of this project are to develop a novel non-invasive test of insulin resistance. The proposed test is based on the well-established principle of inverse relationship between glucose oxidation (Gox) and lipid oxidation (Lox) during cellular respiration. Because the ratio of whole-body Gox/Lox can be measured precisely after administration of a standard dose of 13C-glucose as part of an oral glucose tolerance test (OGTT) based on isotopic analyses of breath CO2, we propose that a suitable noninvasive test of insulin resistance can be developed. During Phase-I, we propose to conduct a limited clinical protocol in individuals who vary across a range of insulin resistance, in order to demonstrate the expected inverse relationship between the proposed test and the currently most useful clinical test of insulin resistance; viz., the whole-body insulin sensitivity index (WBISI). During Phase-H, we will conduct a number of clinical protocols designed specifically to examine the impact of potentially important parameters (experimental and physiological) on performance parameters of this test. We expect that successful completion of research proposed for Phase-I and Phase-H leads to a proprietary product-method specifically for non-invasive assessment of insulin resistance.